Data by Sector within the Total Market
|
| |
Marketcap |
Revenues (TTM) |
Net Income (TTM) |
Employees |
| Sector |
(Millions) |
(Millions) |
(Millions) |
Number |
| Basic Materials Sector |
$ 2,709,242 |
$ 1,734,875 |
$ 95,159 |
2,634,290 |
| Capital Goods Sector |
$ 3,120,439 |
$ 1,418,373 |
$ 111,006 |
2,706,512 |
| Conglomerates Sector |
$ 356,811 |
$ 126,780 |
$ 9,331 |
299,659 |
| Consumer Discretionary Sector |
$ 5,554,916 |
$ 2,921,953 |
$ 112,635 |
3,890,319 |
| Consumer Non Cyclical Sector |
$ 2,629,149 |
$ 1,250,352 |
$ 123,743 |
2,443,335 |
| Energy Sector |
$ 3,365,985 |
$ 2,821,545 |
$ 305,529 |
1,068,766 |
| Financial Sector |
$ 11,461,081 |
$ 4,910,444 |
$ 784,149 |
6,620,679 |
| Healthcare Sector |
$ 6,516,937 |
$ 1,495,959 |
$ 73,420 |
4,021,470 |
| Services Sector |
$ 8,178,433 |
$ 3,201,735 |
$ 193,430 |
10,839,420 |
| Technology Sector |
$ 25,466,720 |
$ 3,727,371 |
$ 543,412 |
6,747,222 |
| Transportation Sector |
$ 941,696 |
$ 701,717 |
$ 43,666 |
2,036,128 |
| Utilities Sector |
$ 2,094,416 |
$ 1,142,805 |
$ 125,310 |
657,246 |
| Retail Sector |
$ 5,797,662 |
$ 4,990,187 |
$ 118,348 |
10,835,905 |
| Total Total Market |
$ 78,193,488 |
$ 30,444,095 |
$ 2,639,137 |
54,800,951 |
Recent News from Total Market |
|
Merger and Acquisition
Plains All American Pipeline Moves Forward with $1 Billion Senior Notes Offering Amid Promising Growth TrajectoryHOUSTON, Jan. 13, 2025 ? In a strategic move indicative of its unwavering commitment to growth and financial stability, Plains All American Pipeline, L.P. (Nasdaq: PAA) unveiled its plans to raise $1 billion through an underwritten public offer...
|
|
|
Management Announcement
Sysco Corporation's Commitment to Employee Welfare Amid Union Strikes: A Balance of Economic Growth and Community SupportIn a proactive measure reflecting its commitment to employee welfare, Sysco Corporation has announced substantial wage increases, enhanced benefits, and additional time off for its Houston colleagues. This move comes at a crucial time ...
|
|
|
Business Update
Innovative Advances in Urothelial Cancer Treatment: Bicycle Therapeutics Updates on Zelenectide Pevedotin and Future DirectionsBicycle Therapeutics plc (NASDAQ: BCYC), a pioneer at the forefront of pharmaceutical innovation, recently revealed promising new data regarding its investigational treatment, zelenectide pevedotin, in a Phase 1 clinical trial. T...
|
|
|
Business Update
Revolutionizing the Wearable Health Tech Industry: Zepp Health Unveils Innovative Solutions at CES 2023 In the bustling corridors of CES Pepcom and ShowStoppers, nestled within the radiant embrace of Las Vegas, Zepp Health Corporation (NYSE: ZEPP) distinguished itself yet again as a vanguard in the domains of smart wearables and health technologies. Headq...
|
|
|
Business Update
In a significant move aimed at bolstering its presence in the burgeoning sports betting landscape, PENN Entertainment, Inc. (NASDAQ: PENN) has announced a long-term partnership with Monumental Sports and Entertainment (MSE). This alliance marks a strategic entry into the Washington, D.C. market, aligning PENN s ambitions in the rapidly evolving online spo...
|
|
|
Business Update
In a revealing announcement, AtriCure, Inc. (NASDAQ: ATRC), a pioneering entity in surgical treatments for atrial fibrillation (Afib) and related health issues, disclosed its preliminary financial results for the fourth quarter and full year of 2024. As the company gears up for its upcoming Analyst and Investor Day scheduled for March 26, 2025, in Mason, ...
|
|
|
Business Update
Aditxt Sets Sights on IPO for Pearsanta: Implications for the Future of Early Cancer Detection In a significant move poised to reshape the landscape of early cancer detection, Aditxt, Inc. (NASDAQ: ADTX) has announced that its Board of Directors has unanimously approved a plan to position its subsidiary, Pearsanta, Inc., for an initial public offering (IP...
|
|
|
Management Announcement
BridgeBio Pharma: Navigating the Dichotomy of Rising Demand and Pertinent Financial LossesIn the realm of biotechnology, where innovation is as commendable as it is hazardous, BridgeBio Pharma Inc. stands at a crossroads. The Palo Alto-based company has recently reported remarkable strides in its portfolio, particularly concerning treatments for genetic...
|
|
|
Announcement
U.S. Global Investors, Inc. (Nasdaq: GROW), a registered investment advisory firm based in San Antonio, Texas, has reported encouraging results for its thematic and smart beta 2.0 exchange-traded funds (ETFs) in 2024. The company atrributed the success to its quantitative strategy, which focuses on selecting high-quality stocks and constructing resilient ...
|
|
|
Announcement
Neurodegenerative diseases such as Alzheimer s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) pose significant challenges in both clinical treatment and research. As these diseases progress, the toxic accumulation of misfolded proteins contributes to neuronal degeneration and loss of function. ProMIS Neurosciences In...
|
|
|
Management Announcement
ASP Isotopes Inc. Faces Legal Challenges Amid Investor Updates in South AfricaThis week, ASP Isotopes Inc. (NASDAQ: ASPI) welcomed a global group of institutional investors to its facilities in Pretoria, South Africa, for a two-day investor access event. The event was aimed at providing updates on the company's ongoing projects, particularly its Silicon-...
|
|
|
Business Update
Lazard, Inc. (NYSE: LAZ), a leading financial advisory and asset management firm, announced its preliminary assets under management (AUM) for the quarter ending December 31, 2024, totaling approximately $226.3 billion. The announcement, made on the first day of the New Year, reveals crucial insights into the company s operational performance and the wider...
|
|
|
Management Announcement
In a bold move amidst a challenging financial landscape, NAYA Biosciences has announced the pricing of a public offering amounting to $9.5 million, underscoring its commitment to advancing treatments in oncology, autoimmune diseases, and women's health. On January 13, 2025, the company revealed plans to offer 13,615,171 units at a price of $0.70 per unit,...
|
|
|
Management Announcement
Scilex Holding Company Faces Financial Strain Amid New Study on ZTlido vs. Lidocaine PatchScilex Holding Company Announces Pain Medicine Study and Financial Challenges'Palo Alto, CA ? January 13, 2025 ?' Scilex Holding Company (Nasdaq: SCLX), a company dedicated to the development and commercialization of non-opioid pain management therapies, finds itself...
|
|
|
Management Announcement
In the rapidly evolving healthcare sector, NeurAxis Inc. (NYSE American: NRXS) is a notable player, focusing on the commercialization of neuromodulation therapies aimed at alleviating chronic ailments in both children and adults. A recent letter from CEO Brian Carrico to shareholders provided insights into the company?s trajectory, including achievements ...
|
|
|
Product Service News
In an ambitious update, Tarsus Pharmaceuticals delineated its strategic progress toward establishing ocular rosacea as a pivotal therapeutic opportunity within the eye care sector, targeting launch dates as early as 2025. The definitive plan includes advancing their novel treatment candidate, TP-04 (lotilaner ophthalmic gel), through the initiation of a P...
|
|
|
Announcement
WISeKey International Holding AG, a leading cybersecurity and IoT company, is set to launch a new-generation satellite through its subsidiary, WISeSat.Space, on January 14, 2025. This project marks a significant milestone in the company?s broader strategy to create a global satellite constellation aimed at enhancing communication capabilities, particularl...
|
|
|
Management Announcement
Foremost Clean Energy's Strategic Spin-Out: A Bold Move to Enhance Shareholder Value Amidst Industry ChallengesForemost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT), a rising force in the North American uranium and lithium exploration sectors, has recently announced a significant development that aims to reshape its corporate structure and maximize shareh...
|
|
|
Management Announcement
Lifeward Ltd. (Nasdaq: LFWD), a key player in the healthcare sector focused on rehabilitation and recovery solutions, recently issued a year-end open letter to shareholders detailing its operational and commercial priorities for 2025. The letter provides insights into the company's recent performance, financial health, and strategic direction, signaling a...
|
|
|
Management Changes
Alignment Healthcare Celebrates Record Membership Growth and Strategic Expansion, Promoting Dawn Maroney to PresidentIn an impressive display of momentum within the Medicare Advantage sector, Alignment Healthcare, Inc. has announced a remarkable 35% year-over-year increase in health plan membership, bringing its total to approximately 209,900 members as o...
|
|
|
Product Service News
Ardelyx Inc has recently provided an update that illuminates its evolving commercial landscape and strategic priorities, aimed at enhancing its position within the pharmaceutical industry. Following a notable ascent in commercial momentum throughout 2024, the company recorded net product sales revenue of approximately $319 million in the United States, an...
|
|
|
Management Announcement
Denali Therapeutics Sets Ambitious 2025 Milestones Despite Financial StrugglesDenali Therapeutics Inc., a biotech firm focused on developing therapies for neurodegeneration and lysosomal storage diseases, recently outlined its key anticipated milestones for 2025. The company?s Chief Executive Officer, Ryan Watts, Ph.D., is scheduled to present these goal...
|
|
|
Management Announcement
As the biotech sector grapples with economic headwinds, Cogent Biosciences Inc. stands at a pivotal juncture in its mission to advance targeted therapies for cancer. Despite its cumulative net loss of $242 million over the past year, the company is forging ahead with ambitious milestones for its lead drug, Bezuclastinib, and its new portfolio of selective...
|
|
|
Clinical Study
Soquelitinib Shines in Phase 1 Trial for Atopic Dermatitis: Promising Safety and Efficacy Profile Unveiled In a significant leap forward in the management of atopic dermatitis, Corvus Pharmaceuticals has announced promising findings from Cohort 2 of its placebo-controlled Phase 1 clinical trial of Soquelitinib. The latest data emphasize its potential as a...
|
|
|
Clinical Study
In a significant development for Alzheimer?s disease treatment, recent findings from the ATTENTION-AD trial demonstrate that over three years of continuous treatment with oral Blarcamesine has resulted in substantial cognitive and functional improvements among early-stage Alzheimer?s disease patients. This Phase IIb/III clinical trial adds pivotal data to...
|
|
|
Product Service News
Gene Editing?s Next Leap: Verve Therapeutics Charts New Territory with Promising Pipeline In the fast-evolving landscape of biotechnology, Verve Therapeutics is charting a bold course toward the future of precision medicine, despite a challenging performance on the stock market. With a focus on pioneering treatments through gene editing, Verve is steering...
|
|
|
Announcement
for CSIMarket.com : Legal Counsel Urged for Rentokil Initial PLC Investors Amid Class Action Lawsuit In a recent development that has captured the attention of the financial community, the Rosen Law Firm, a prominent global investor rights firm, has issued a reminder to investors in Rentokil Initial PLC regarding a looming deadline in an ongoing securit...
|
|
|
Announcement
In the dynamic world of gaming and entertainment, Light and Wonder, Inc. (NASDAQ: LNW) finds itself under the spotlight, both for its financial performance and recent allegations regarding its business disclosures. The global investor rights law firm, Rosen Law Firm, has initiated an investigation into potential securities claims on behalf of shareholders...
|
|
|
Announcement
The Unisys Quandary: A Call to Investors Amid Financial UncertaintiesIn a troubling turn of events, Unisys Corporation (NYSE: UIS) finds itself embroiled in accusations that it may have disseminated materially misleading information to the investing public. The implications of such allegations have spurred The Rosen Law Firm, a global champion of investo...
|
|
|
Announcement
Replimune Group, Inc. Inducement Grants Overview Replimune Group, Inc. (NASDAQ: REPL), a biotechnology firm engaged in the development of innovative oncolytic immunotherapies, recently issued a press release regarding the grant of inducement equity awards to newly hired non-executive employees. This announcement, made on January 10, 2025, aligns with the ...
|
|
|
|
|
|
